Phillip J Stevens1, Masaru Sekido, Robert J Lee. 1. Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA.
Abstract
PURPOSE: The anticancer drug paclitaxel has poor aqueous solubility and is difficult to formulate in a lipid-based formulation due to its limited lipid solubility. Paclitaxel-7-carbonyl-cholesterol (Tax-Chol), a prodrug of paclitaxel with increased lipophilicity, was therefore synthesized and evaluated for incorporation into a lipid nanoparticle (LN) formulation, which also contained folate-polyethylene glycolcholesterol (f-PEG-Chol) as a ligand that targets the tumor marker folate receptor (FR). This novel formulation was designed for prolonged systemic circulation and selective targeting of tumor cells with amplified FR expression. METHODS: Tax-Chol was synthesized. FR-targeted LNs, composed of distearoyl phosphatidylcholine (DSPC)/triolein/Chol oleate/PEG-Chol/f-PEG-Chol (40:40:18:2.0:0.5, mole/mole), were then prepared by solvent dilution followed by diafiltration. FR-targeted LNs containing Tax-Chol were then evaluated for cytotoxicity in KB, a human oral carcinoma cell line, and M109, a murine lung carcinoma cell line, both of which are FR(+) and in FR(-) Chinese hamster ovary (CHO) cells. Furthermore, tumor growth inhibition and animal survival in response to treatment with FR-targeted LNs and control formulations were evaluated in BALB/c mice bearing subcutaneously engrafted M109 tumors. RESULTS: The LNs had a mean diameter of 130 nm and Tax-Chol incoporation efficiency of greater than 90% and exhibited excellent colloidal stability. FR-targeted LNs showed greater uptake and cytotoxicity in FR(+) KB and M109 cells than nontargeted LNs. Furthermore, treatment of mice bearing M109 tumors with FR-targeted LNs resulted in significantly greater tumor growth inhibition and animal survival compared to treatment with nontargeted LNs or paclitaxel formulated in Cremophor EL. CONCLUSION: FR-targeted LNs containing Tax-Chol are a promising novel formulation for the treatment of FR(+) tumors and further preclinical studies are warranted.
PURPOSE: The anticancer drug paclitaxel has poor aqueous solubility and is difficult to formulate in a lipid-based formulation due to its limited lipid solubility. Paclitaxel-7-carbonyl-cholesterol (Tax-Chol), a prodrug of paclitaxel with increased lipophilicity, was therefore synthesized and evaluated for incorporation into a lipid nanoparticle (LN) formulation, which also contained folate-polyethylene glycolcholesterol (f-PEG-Chol) as a ligand that targets the tumor marker folate receptor (FR). This novel formulation was designed for prolonged systemic circulation and selective targeting of tumor cells with amplified FR expression. METHODS:Tax-Chol was synthesized. FR-targeted LNs, composed of distearoyl phosphatidylcholine (DSPC)/triolein/Chol oleate/PEG-Chol/f-PEG-Chol (40:40:18:2.0:0.5, mole/mole), were then prepared by solvent dilution followed by diafiltration. FR-targeted LNs containing Tax-Chol were then evaluated for cytotoxicity in KB, a humanoral carcinoma cell line, and M109, a murinelung carcinoma cell line, both of which are FR(+) and in FR(-) Chinese hamster ovary (CHO) cells. Furthermore, tumor growth inhibition and animal survival in response to treatment with FR-targeted LNs and control formulations were evaluated in BALB/c mice bearing subcutaneously engrafted M109 tumors. RESULTS: The LNs had a mean diameter of 130 nm and Tax-Chol incoporation efficiency of greater than 90% and exhibited excellent colloidal stability. FR-targeted LNs showed greater uptake and cytotoxicity in FR(+) KB and M109 cells than nontargeted LNs. Furthermore, treatment of mice bearing M109 tumors with FR-targeted LNs resulted in significantly greater tumor growth inhibition and animal survival compared to treatment with nontargeted LNs or paclitaxel formulated in Cremophor EL. CONCLUSION: FR-targeted LNs containing Tax-Chol are a promising novel formulation for the treatment of FR(+) tumors and further preclinical studies are warranted.
Authors: Jennifer J Sudimack; Dianne Adams; Joan Rotaru; Supriya Shukla; Junhua Yan; Masaru Sekido; Rolf F Barth; Werner Tjarks; Robert J Lee Journal: Pharm Res Date: 2002-10 Impact factor: 4.200
Authors: H Hashizume; P Baluk; S Morikawa; J W McLean; G Thurston; S Roberge; R K Jain; D M McDonald Journal: Am J Pathol Date: 2000-04 Impact factor: 4.307
Authors: Paul Galvin; Damien Thompson; Katie B Ryan; Anna McCarthy; Anne C Moore; Conor S Burke; Maya Dyson; Brian D Maccraith; Yurii K Gun'ko; Michelle T Byrne; Yuri Volkov; Chris Keely; Enda Keehan; Michael Howe; Conor Duffy; Ronan MacLoughlin Journal: Cell Mol Life Sci Date: 2011-10-21 Impact factor: 9.261
Authors: Cory D Sago; Melissa P Lokugamage; Gwyneth N Lando; Naima Djeddar; Nirav N Shah; Chris Syed; Anton V Bryksin; James E Dahlman Journal: Nano Lett Date: 2018-09-20 Impact factor: 11.189
Authors: Jilong Li; Subhadip Ghatak; Mohamed S El Masry; Amitava Das; Yang Liu; Sashwati Roy; Robert J Lee; Chandan K Sen Journal: Mol Ther Date: 2018-04-27 Impact factor: 11.454